#3081 ASSOCIATION OF URINE PROTEIN EXCRETION LEVELS, AS A MEASURE OF DISEASE ACTIVITY, AND QUALITY OF LIFE IN IGA NEPHROPATHY PATIENTS

Abstract Background and Aims Little is known about the quality of life (QoL) patients with IgA nephropathy (IgAN). Understanding relationship between disease activity (as measured by urine protein excretion [UPE]) QoL could allow decision-makers to understand how treatments that improve UPE might patient QoL. Methods The 2021 United States subset Adelphi IgAN Disease Specific Programme™ was a point-in-time survey 43 nephrologists (who completed structured forms for 305 patients) 70 elected complete surveys 305). This analysis utilised physician-reported data (patient demographics, characteristics, current 24-hour levels [categories: ≤0.5, >0.5 ≤1, >1 ≤2, >2 ≤3.5, >3.5 grams/day]) patient-reported (symptoms, Kidney Quality Life [KDQOL] scores, EQ-5D scores). association symptoms evaluated using chi-squared Fisher's exact tests. (KDQOL, EQ-5D) generalized linear regression adjust age, sex, chronic kidney stage, corticosteroid use, non-steroidal immunosuppressant use. Results analytical dataset included 69 (reported 8 physicians) out who survey. Of these 69, were (n=63), KDQOL (n=60), (n=67). Patients an average age years, BMI 26.3, 49% male, 55% White, 23% Asian, 64% never smokers, 78% in full-time occupation, 74% commercial health insurance. most prevalent comorbidities hypertension (33%), hyperlipidemia (30%), diabetes (11%). not associated any demographic regular dialysis, or transplants. Among comorbidities, higher percentage hyperlipidaemia (P = .03). medications IgAN, percent use diuretics .046), sodium-glucose co-transporter 2 inhibitors .002), corticosteroids .0009), immunosuppressants (p<0.0001), anti-depressants .0009). Higher aching joints .04), self-awareness high cholesterol .001), tiredness .005), swollen feet/ankles/legs sleep problems .02), feeling sick .0003), tea-colored worse scores (burden [p<0.0001], effects [P .007], physical .002], mental [p<0.0001]). After adjustment (Table 1), continued be burden .01) .03) scores. Unadjusted adjusted analyses 2) indicated Conclusion results indicate (UPE) are increased symptom burden, QoL, overall